Peroxisome proliferator-activated receptors protect against apoptosis via 14-3-3

PPAR Research

Volumn , Issue , 2010, Pages

  Wu, Kenneth K ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BAX; ROSIGLITAZONE; TRANSCRIPTION FACTOR FOXO;

APOPTOSIS; BRAIN INFARCTION; CELL DEATH; CELL PROTECTION; DRUG RECEPTOR BINDING; ISCHEMIA; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; TISSUE INJURY; UPREGULATION;

EID: 77957960820     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/417646     Document Type: Review

References (62)

1. Robinson E., Grieve D. J., Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease Pharmacology and Therapeutics 2009 122 3 246 263
2. Bishop-Bailey D., Bystrom J., Emerging roles of peroxisome proliferator-activated receptor- / in inflammation Pharmacology and Therapeutics 2009 124 2 141 150
3. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease Nature 2000 405 6785 421 424
4. Liou J.-Y., Lee S., Ghelani D., Matijevic-Aleksic N., Wu K. K., Protection of endothelial survival by peroxisome proliferator-activated receptor- mediated 14-3-3 upregulation Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 7 1481 1487
5. Wu K. K., Liou J.-Y., Cellular and molecular biology of prostacyclin synthase Biochemical and Biophysical Research Communications 2005 338 1 45 52
6. Pober J. S., Cotran R. S., Cytokines and endothelial cell biology Physiological Reviews 1990 70 2 427 451
7. Bunting S., Moncada S., Vane J. R., The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications British Medical Bulletin 1983 39 3 271 276
8. Oates J. A., FitzGerald G. A., Branch R. A., Jackson E. K., Knapp H. R., Roberts L. J. II, Clinical implications of prostaglandin and thromboxane A2 formation (first of two parts) New England Journal of Medicine 1988 319 11 689 698
9. Hata A. N., Breyer R. M., Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacology and Therapeutics 2004 103 2 147 166
10. Adderley S. R., Fitzgerald D. J., Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediate induction of cyclooxygenase-2 Journal of Biological Chemistry 1999 274 8 5038 5046
11. Hao C.-M., Kmhoff M., Guan Y., Redha R., Breyer M. D., Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival American Journal of PhysiologyRenal Physiology 1999 277 3, part 2 F352 F359
12. Pozner R. G., Negrotto S., D'Atri L. P., Kotler M. L., Lazzari M. A., Gomez R. M., Schattner M., Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis British Journal of Pharmacology 2005 145 3 283 292
13. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317
14. Hao C.-M., Redha R., Morrow J., Breyer M. D., Peroxisome proliferator-activated receptor activation promotes cell survival following hypertonic stress Journal of Biological Chemistry 2002 277 24 21341 21345
15. Di-Po N., Tan N. S., Michalik L., Wahli W., Desvergne B., Antiapoptotic role of PPAR in keratinocytes via transcriptional control of the Akt1 signaling pathway Molecular Cell 2002 10 4 721 733
16. Pesant M., Sueur S., Dutartre P., Tallandier M., Grimaldi P. A., Rochette L., Connat J.-L., Peroxisome proliferator-activated receptor (PPAR ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovascular Research 2006 69 2 440 449
17. Wan J., Jiang L., L Q., Ke L., Li X., Tong N., Activation of PPAR up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic -cells Biochemical and Biophysical Research Communications 2010 391 3 1567 1572
18. Kim H. J., Kim M. Y., Jin H., Kim H. J., Kang S. S., Kim H. J., Lee J. H., Chang K. C., Hwang J.-Y., Yabe-Nishimura C., Kim J.-H., Seo H. G., Peroxisome proliferator-activated receptor regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor- 1/Smad3 Circulation Research 2009 105 1 16 24
19. Lin H., Lin T.-N., Cheung W.-M., Nian G.-M., Tseng P.-H., Chen S.-F., Chen J.-J., Shyue S.-K., Liou J.-Y., Wu C.-W., Wu K. K., Cyclooxygenase-1 and bicistronic cyclooxygenase-1/ prostacyclin synthase gene transfer protect against ischemic cerebral infarction Circulation 2002 105 16 1962 1969
20. Fu H., Subramanian R. R., Masters S. C., 14-3-3 Proteins: structure, function, and regulation Annual Review of Pharmacology and Toxicology 2000 40 617 647
21. Morrison D. K., The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development Trends in Cell Biology 2009 19 1 16 23
22. Liou J.-Y., Matijevic-Aleksic N., Lee S., Wu K. K., Prostacyclin inhibits endothelial cell XIAP ubiquitination and degradation Journal of Cellular Physiology 2007 212 3 840 848
23. Shiff S. J., Qiao L., Tsai L.-L., Rigas B., Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells Journal of Clinical Investigation 1995 96 1 491 503
24. DuBois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B. A., Lipsky P. E., Cyclooxygenase in biology and disease FASEB Journal 1998 12 12 1063 1073
25. Piazza G. A., Alberts D. S., Hixson L. J., Paranka N. S., Li H., Finn T., Bogert C., Guillen J. M., Brendel K., Gross P. H., Sperl G., Ritchie J., Burt R. W., Ellsworth L., Ahnen D. J., Pamukcu R., Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Research 1997 57 14 2909 2915
26. Gupta R. A., Tan J., Krause W. F., Geraci M. W., Willson T. M., Dey S. K., DuBois R. N., Prostacyclin-mediated activation of peroxisome proliferator-activated receptor in colorectal cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 24 13275 13280
27. Gupta R. A., Wang D., Katkuri S., Wang H., Dey S. K., DuBois R. N., Activation of nuclear hormone receptor peroxisome proliferator-activated receptor- accelerates intestinal adenoma growth Nature Medicine 2004 10 3 245 247 (Pubitemid 38667613)
28. He T.-C., Chan T. A., Vogelstein B., Kinzler K. W., PPAR is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 1999 99 3 335 345
29. Liou J.-Y., Ghelani D., Yeh S., Wu K. K., Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3 Cancer Research 2007 67 7 3185 3191
30. Liou J.-Y., Wu C.-C., Chen B.-R., Yen L. B., Wu K. K., Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor- transcriptional pathway Molecular Pharmacology 2008 74 5 1399 1406
31. Ho T.-C., Chen S.-L., Yang Y.-C., Liao C.-L., Cheng H.-C., Tsao Y.-P., PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells Cardiovascular Research 2007 76 2 213 223
32. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., Hiwada K., Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells European Journal of Pharmacology 2000 407 3 227 235
33. Kilter H., Werner M., Roggia C., Reil J.-C., Schfers H.-J., Kintscher U., Bhm M., The PPAR- agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation Diabetes, Obesity and Metabolism 2009 11 11 1060 1067
34. Lin C.-Y., Gurlo T., Haataja L., Hsueh W. A., Butler P. C., Activation of peroxisome proliferator-activated receptor- by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway Journal of Clinical Endocrinology and Metabolism 2005 90 12 6678 6686
35. Wu J.-S., Cheung W.-M., Tsai Y.-S., Chen Y.-T., Fong W.-H., Tsai H.-D., Chen Y.-C., Liou J.-Y., Shyue S.-K., Chen J.-J., Chen Y. E., Maeda N., Wu K. K., Lin T.-N., Ligand-activated peroxisome proliferator-activated receptor- protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 upregulation Circulation 2009 119 8 1124 1134
36. Hinz B., Brune K., Pahl A., 15-Deoxy- 12,14-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR- -independent mechanism Biochemical and Biophysical Research Communications 2003 302 2 415 420
37. Lynn Wang Y., Frauwirth K. A., Rangwala S. M., Lazar M. A., Thompson C. B., Thiazolidinedione activation of peroxisome proliferator-activated receptor can enhance mitochondrial potential and promote cell survival Journal of Biological Chemistry 2002 277 35 31781 31788
38. Lin T.-N., Cheung W.-M., Wu J.-S., Chen J.-J., Lin H., Chen J.-J., Liou J.-Y., Shyue S.-K., Wu K. K., 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 3 481 487
39. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82
40. Jiang C., Ting A. T., Seed B., PPAR- agonists inhibit production of monocyte inflammatory cytokines Nature 1998 391 6662 82 86
41. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R. A., Martinez G., Inestrosa N. C., Bronfman M., Peroxisome proliferator-activated receptor up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis Journal of Biological Chemistry 2007 282 51 37006 37015
42. Wu J.-S., Lin T.-N., Wu K. K., Rosiglitazone and PPAR- overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins Journal of Cellular Physiology 2009 220 1 58 71
43. Barbier O., Torra I. P., Duguay Y., Blanquart C., Fruchart J.-C., Glineur C., Staels B., Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 5 717 726
44. Lefebvre P., Chinetti G., Fruchart J.-C., Staels B., Sorting out the roles of PPAR in energy metabolism and vascular homeostasis Journal of Clinical Investigation 2006 116 3 571 580
45. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J. M., Gonzalez F. J., Fruchart J.-C., Tedgui A., Haegeman G., Staels B., Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- B and AP-1 Journal of Biological Chemistry 1999 274 45 32048 32054
46. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., Delerive P., Fadel A., Chinetti G., Fruchart J.-C., Najib J., Maclouf J., Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators Nature 1998 393 6687 790 793
47. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131
48. Wayman N. S., Hattori Y., Mcdonald M. C., Mota-Filipe H., Cuzzocrea S., Pisano B., Chatterjee P. K., Thiemermann C., Ligands of the peroxisome proliferator-activated receptors (PPAR- and PPAR- ) reduce myocardial infarct size FASEB Journal 2002 16 9 1027 1040 (Pubitemid 34753509)
49. Inoue I., Goto S.-I., Matsunaga T., Nakajima T., Awata T., Hokari S., Komoda T., Katayama S., The ligands/activators for peroxisome proliferator-activated receptor (PPAR ) and PPAR increase Cu 2+,Zn 2+ -superoxide dismutase and decrease p22phox message expressions in primary endothelial cells Metabolism 2001 50 1 3 11
50. Poynter M. E., Daynes R. A., Peroxisome proliferator-activated receptor activation modulates cellular redox status, represses nuclear factor- B signaling, and reduces inflammatory cytokine production in aging Journal of Biological Chemistry 1998 273 49 32833 32841
51. Deplanque D., Gel P., Ptrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.-C., Cecchelli R., Staels B., Duriez P., Bordet R., Peroxisome proliferator-activated receptor- activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment Journal of Neuroscience 2003 23 15 6264 6271
52. Chen H.-H., Chen T.-W., Lin H., Prostacyclin-induced peroxisome proliferator-activated receptor- translocation attenuates NF- B and TNF- activation after renal ischemia-reperfusion injury American Journal of PhysiologyRenal Physiology 2009 297 4 F1109 F1118
53. Li S., Bhatt R., Megyesi J., Gokden N., Shah S. V., Portilla D., PPAR- ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G American Journal of PhysiologyRenal Physiology 2004 287 5 F990 F998
54. Lin H., Hou C.-C., Cheng C.-F., Chiu T.-H., Hsu Y.-H., Sue Y.-M., Chen T.-H., Hou H.-H., Chao Y.-C., Cheng T.-H., Chen C.-H., Peroxisomal proliferator-activated receptor- protects renal tubular cells from doxorubicin-induced apoptosis Molecular Pharmacology 2007 72 5 1238 1245
55. Chen H.-H., Sue Y.-M., Chen C.-H., Hsu Y.-H., Hou C.-C., Cheng C.-Y., Lin S.-L., Tsai W.-L., Chen T.-W., Chen T.-H., Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells Nephrology Dialysis Transplantation 2009 24 10 3042 3049
56. De Silva D. S., Wilson R. M., Hutchinson C., Ip P. C., Garcia A. G., Lancel S., Ito M., Pimentel D. R., Sam F., Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms American Journal of PhysiologyHeart and Circulatory Physiology 2009 296 6 H1983 H1993
57. Wu Q. N., Tang Q., Xiao Q., Wu P., Gao A., Li L., PPARalpha agonist prevented the apoptosis induced by glucose and fatty acid in neonatal cardiomyocytes. Journal of Endocrinological Investigation. In press
58. Hengartner M. O., The biochemistry of apoptosis Nature 2000 407 6805 770 776
59. Datta S. R., Katsov A., Hu L., Petros A., Fesik S. W., Yaffe M. B., Greenberg M. E., 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation Molecular Cell 2000 6 1 41 51
60. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J., Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 1996 87 4 619 628
61. Nomura M., Shimizu S., Sugiyama T., Narita M., Ito T., Matsuda H., Tsujimoto Y., 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax Journal of Biological Chemistry 2003 278 3 2058 2065
62. Han J. K., Lee H. S., Yang H. M., Peroxisome proliferator-activated receptor- agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway Circulation 2008 118 10 1021 1033